IL6 and COVID-19: Besides the role of JAK-STAT in CRS downstream IL-6 axis activation in COVID-19, it has been reported in a recent study that SARS-CoV-2 may disrupt JAK-STAT pathway components as a counteractive action to tackle IFN-mediated antiviral responses, facilitating virus replication in diverse tissue types [131].